Baseline demographic and clinical characteristics of patients
| Characteristic . | RARA overexpression status∗ . | ||
|---|---|---|---|
| RARA-positive (n = 22) . | RARA-negative (n = 29) . | Total (N = 51) . | |
| Age | |||
| Median (range), y | 77 (60-91) | 76 (64-86) | 76 (60-91) |
| ≥75 y, n (%) | 16 (73) | 15 (52) | 31 (61) |
| Male sex, n (%) | 13 (59) | 19 (66) | 32 (63) |
| AML type, n (%)† | |||
| De novo | 16 (73) | 13 (45) | 29 (57) |
| Secondary | 6 (27) | 16 (55) | 22 (43) |
| Evolved from antecedent hematologic malignancy | 6 (27) | 13 (45) | 19 (37) |
| Associated with treatment from prior malignancy | 0 (0) | 3 (10) | 3 (6) |
| AML cytogenetic risk category, n (%)‡ | |||
| Intermediate | 16 (73) | 18 (62) | 34 (67) |
| Poor | 6 (27) | 10 (34) | 16 (31) |
| Not determined | 0 (0) | 1 (4) | 1 (2) |
| Hypomethylating agent prior cancer treatment, n (%) | |||
| Any hypomethylating agent | 2 (9) | 6 (21) | 8 (16) |
| Azacitidine | 2 (9) | 3 (10) | 5 (10) |
| Decitabine | 0 (0) | 3 (10) | 3 (6) |
| Baseline bone marrow blasts, n (%) | |||
| ≤30% (low–blast count AML) | 7 (32) | 11 (38) | 18 (35) |
| >30% | 15 (68) | 18 (62) | 33 (65) |
| Eastern Cooperative Oncology Group performance status score, n (%)§ | |||
| 0-1 | 12 (55) | 18 (62) | 30 (59) |
| 2-3 | 8 (36) | 10 (34) | 18 (35) |
| Missing | 2 (9) | 1 (4) | 3 (6) |
| Characteristic . | RARA overexpression status∗ . | ||
|---|---|---|---|
| RARA-positive (n = 22) . | RARA-negative (n = 29) . | Total (N = 51) . | |
| Age | |||
| Median (range), y | 77 (60-91) | 76 (64-86) | 76 (60-91) |
| ≥75 y, n (%) | 16 (73) | 15 (52) | 31 (61) |
| Male sex, n (%) | 13 (59) | 19 (66) | 32 (63) |
| AML type, n (%)† | |||
| De novo | 16 (73) | 13 (45) | 29 (57) |
| Secondary | 6 (27) | 16 (55) | 22 (43) |
| Evolved from antecedent hematologic malignancy | 6 (27) | 13 (45) | 19 (37) |
| Associated with treatment from prior malignancy | 0 (0) | 3 (10) | 3 (6) |
| AML cytogenetic risk category, n (%)‡ | |||
| Intermediate | 16 (73) | 18 (62) | 34 (67) |
| Poor | 6 (27) | 10 (34) | 16 (31) |
| Not determined | 0 (0) | 1 (4) | 1 (2) |
| Hypomethylating agent prior cancer treatment, n (%) | |||
| Any hypomethylating agent | 2 (9) | 6 (21) | 8 (16) |
| Azacitidine | 2 (9) | 3 (10) | 5 (10) |
| Decitabine | 0 (0) | 3 (10) | 3 (6) |
| Baseline bone marrow blasts, n (%) | |||
| ≤30% (low–blast count AML) | 7 (32) | 11 (38) | 18 (35) |
| >30% | 15 (68) | 18 (62) | 33 (65) |
| Eastern Cooperative Oncology Group performance status score, n (%)§ | |||
| 0-1 | 12 (55) | 18 (62) | 30 (59) |
| 2-3 | 8 (36) | 10 (34) | 18 (35) |
| Missing | 2 (9) | 1 (4) | 3 (6) |
Data are presented as number (%) unless indicated otherwise.
RARA overexpression was determined in blasts isolated from PBMCs by qRT-PCR assay. The presence of RARA overexpression was characterized as RARA-positive, and the absence of RARA overexpression as RARA-negative.
AML denotes non-APL AML.
Cytogenetic risk was assessed per NCCN AML guidelines 2018.15
Eastern Cooperative Oncology Group performance status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.